Groups Urge Federal Action Against Eclipse Cigarettes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

WASHINGTON-Twenty-two public health organizations have again called on the federal government to initiate action against R.J. Reynolds Co. to stop it from making unsubstantiated health-related claims about its Eclipse cigarette.

WASHINGTON—Twenty-two public health organizations have again called on the federal government to initiate action against R.J. Reynolds Co. to stop it from making unsubstantiated health-related claims about its Eclipse cigarette.

In separate letters to the Department of Health and Human Services (HHS), the FDA, and the Federal Trade Commission, the groups contended that a failure to act "is tantamount to a license to Reynolds and other tobacco companies to make unsubstantiated and unproven health claims with impunity and without fear of federal oversight."

In their letter to HHS Secretary Tommy Thompson, the health organizations cited a recent report by the Institute of Medicine, which concluded that none of the so-called reduced risk tobacco products have proven less hazardous than standard cigarettes.

Eclipse uses a charcoal heat source containing a small amount of tobacco at its tip, which burns. The heat from the burning tip passes through a length of tobacco, which doesn’t burn, and glycerin, which vaporizes. The result is smoke and flavor reaching the smoker.

R.J. Reynolds has claimed that Eclipse has 80% fewer carcinogens in its smoke than do ultralight cigarettes. It currently markets Eclipse in several sections of the country.

Recent Videos
6 experts are featured in this series.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
6 experts are featured in this series.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content